It is Genetics Institute of America’s goal to occupy an industry leadership position through innovative strategic initiatives, high value clinical practices, and superior team member performance. Our state of the art facility in Delray Beach, FL provides cutting edge technology that allows us to specialize in genetic and specialty testing. Learn more about our current clinical studies below:
The objective of our study GH101 (Genetic Susceptibility to Chronic Disease) is to take an integrative approach to the fields of pharmacogenomics, cancer genomics, mRNA microarrays and nutrigenomics. These disciplines have evolved from the original human genome project but have essentially remained discreet. The integration of these genetic disciplines into a computational model has the potential to increase diagnostic yield and provide a clearer genetic picture to determine actionable events to improve healthcare.
GH215 – Urine Analysis for Prostate Cancer will offer doctors a new diagnostic approach for prostate cancer, the second most frequent malignancy (after lung cancer) in men worldwide. Our advanced technology will expand on previous efforts and offer new insights into disease progression; offering healthcare professionals the ability to quickly, inexpensively, and easily diagnose patients if proven successful.
Speak to one of our representatives today to learn more about enrolling your practice in one of our research studies.
Sign up to receive monthly updates on new product announcements, press releases, promotions, and more.
Speak to one of our representatives today to learn more about our CAP and CLIA-accredited laboratory.
Copyright © 2019-2024 Genetics Institute of America. All Rights Reserved.
